This finding offers a novel perspective on the relationship between AFP levels and NAFLD in patients with inactive CHB, contrary to the prevailing understanding linking elevated AFP levels with hepatic steatosis development [83,84,85,86,87]. This evidence concerns the gene AFP and metabolic dysfunction-associated steatotic liver disease.